Novel Combination Therapy for Advanced NSCLC Shows Promise

Swiss Cancer Institute has launched a Phase 2 clinical trial to investigate the efficacy of combining gemcitabine with ivonescimab in patients with advanced non-small cell lung cancer (NSCLC) who have experienced disease progression following chemoimmunotherapy (CIT). The trial aims to enroll 47 participants from the USA and will evaluate the objective response rate (ORR) according to RECIST v1.1 criteria. This combination therapy is expected to offer a novel and effective treatment strategy for patients with relapsed NSCLC, addressing a significant unmet medical need.

Key Takeaways:

• The Phase 2 clinical trial aims to evaluate the efficacy of combining gemcitabine with ivonescimab in patients with advanced NSCLC who have experienced disease progression following CIT.
• The trial will enroll 47 participants from the USA and will be conducted at the Swiss Cancer Institute.
• The combination therapy is expected to enhance antitumor immune responses and inhibit tumor angiogenesis, addressing a significant unmet medical need.
• Gemcitabine has demonstrated immunostimulatory properties, including enhanced T-cell infiltration and reduced immunosuppressive cell populations, which may synergize with immune checkpoint inhibitors.
• Ivonescimab targets both PD-1 and VEGF pathways, potentially inhibiting tumor angiogenesis and enhancing antitumor immune responses.
• The trial aims to evaluate the objective response rate (ORR) according to RECIST v1.1 criteria, providing valuable insights into the efficacy of the combination therapy.
• Lung cancer remains the leading cause of cancer-related death globally, and treatment options after CIT failure are limited, making this combination therapy a promising new approach.

Statistics:

• 47 participants will be enrolled in the Phase 2 clinical trial.
• The trial will be conducted at the Swiss Cancer Institute.
• The potential benefits of the combination therapy include enhanced antitumor immune responses and inhibiting tumor angiogenesis.
• Gemcitabine has demonstrated immunostimulatory properties in previous studies, including enhanced T-cell infiltration and reduced immunosuppressive cell populations.
• Lung cancer accounts for over 1.8 million deaths worldwide each year, making it the leading cause of cancer-related death globally.
• Treatment options after CIT failure are limited, making this combination therapy a promising new approach for patients with relapsed NSCLC.

Sources:

• ClinicalTrials.gov Source: NCT07158489